Kristina McGuire
A5019668595- Cancer Immunotherapy and Biomarkers
- Biosimilars and Bioanalytical Methods
- Lung Cancer Treatments and Mutations
- Cell Image Analysis Techniques
- Child and Adolescent Psychosocial and Emotional Development
- CAR-T cell therapy research
- Evaluation and Performance Assessment
- Youth Development and Social Support
- Pancreatic and Hepatic Oncology Research
- Child Abuse and Trauma
- Criminal Justice and Corrections Analysis
- Religion and Society Interactions
- Religion, Spirituality, and Psychology
- Biosensors and Analytical Detection
- Cancer Genomics and Diagnostics
- Bullying, Victimization, and Aggression
- SARS-CoV-2 detection and testing
- 3D Printing in Biomedical Research
- Resilience and Mental Health
- Substance Abuse Treatment and Outcomes
- Cognitive Abilities and Testing
- Community Health and Development
- Policy Transfer and Learning
- Innovative Microfluidic and Catalytic Techniques Innovation
- Lung Cancer Research Studies
Regeneron (United States)
2021-2025
Virginia Commonwealth University
2018-2021
New York University
2005
Abstract First-line cemiplimab (anti-programmed cell death-1 (PD-1)) monotherapy has previously shown significant improvement in overall survival (OS) and progression-free (PFS) versus chemotherapy patients with advanced non-small lung cancer (aNSCLC) PD-ligand 1 (PD-L1) expression ≥50%. EMPOWER-Lung 3 ( NCT03409614 ), a double-blind, placebo-controlled, phase study, examined plus platinum-doublet as first-line treatment for aNSCLC, irrespective of PD-L1 or histology. In this 466 stage...
Significance This study is an experimental trial that demonstrates the potential for formal outreach strategies to change congressional use of research. Our results show collaboration between policy and research communities can policymakers’ value science result in legislation appears be more inclusive evidence. The findings this also demonstrated changes researchers’ knowledge motivation engage with policymakers as well their actual engagement behavior. Together, observed both researchers...
The 15th edition of the Workshop on Recent Issues in Bioanalysis (15th WRIB) was held 27 September to 1 October 2021. Even with a last-minute move from in-person virtual, an overwhelmingly high number nearly 900 professionals representing pharma and biotech companies, contract research organizations (CROs), multiple regulatory agencies still eagerly convened actively discuss most current topics interest bioanalysis. WRIB included 3 Main Workshops 7 Specialized that together spanned week...
The 15th edition of the Workshop on Recent Issues in Bioanalysis (15th WRIB) was held 27 September to 1 October 2021. Even with a last-minute move from in-person virtual, an overwhelmingly high number nearly 900 professionals representing pharma and biotech companies, contract research organizations (CROs), multiple regulatory agencies still eagerly convened actively discuss most current topics interest bioanalysis. WRIB included three Main Workshops seven Specialized that together spanned...
The 18th Workshop on Recent Issues in Bioanalysis (18th WRIB) took place San Antonio, TX, USA May 6-10, 2024. Over 1100 professionals representing pharma/biotech companies, CROs, and multiple regulatory agencies convened to actively discuss the most current topics of interest bioanalysis. WRIB included 3 Main Workshops 7 Specialized that together spanned 1 week allow an exhaustive thorough coverage all major issues bioanalysis biomarkers, immunogenicity, gene therapy, cell therapy vaccines....
The 14th edition of the Workshop on Recent Issues in Bioanalysis (14th WRIB) was held virtually June 15-29, 2020 with an attendance over 1000 representatives from pharmaceutical/biopharmaceutical companies, biotechnology contract research organizations, and regulatory agencies worldwide. WRIB included three Main Workshops, seven Specialized Workshops that together spanned 11 days order to allow exhaustive thorough coverage all major issues bioanalysis, biomarkers, immunogenicity, gene...
The 16th Workshop on Recent Issues in Bioanalysis (16th WRIB) took place Atlanta, GA, USA September 26–30, 2022. Over 1000 professionals representing pharma/biotech companies, CROs, and multiple regulatory agencies convened to actively discuss the most current topics of interest bioanalysis. WRIB included 3 Main Workshops 7 Specialized that together spanned 1 week order allow exhaustive thorough coverage all major issues bioanalysis, biomarkers, immunogenicity, gene therapy, cell therapy...
This study evaluated sibling effects of a family-based intervention aimed at preventing conduct problems in preschool-age siblings adjudicated youths. Ninety-two families preschoolers who had older for delinquent acts were randomly assigned to and control conditions. Of these, 47 nontargeted school-age (5-11 years) or adolescent (12-17 living home. These considered this report. The authors hypothesized group differences on antisocial behavior positive peer relations targeted preschoolers....